.jpg)
.png)
All
David Neff, DO, has worked closely with the National Lipid Association and its members since 2003, and now volunteers his time as a member to help carry out its mission. Dr. Neff’s interest in lipidology originated from a research assignment that focused on cholesterol fed rodents with fatty liver... more
This year, Familial Hypercholesterolemia (FH) Awareness Day is on September 24, 2016. It was initiated by The FH Foundation as part of their mission to raise awareness of FH in the public. The FH Foundation is a patient-centered nonprofit organization dedicated to education,... more
The NLA would like to congratulate the winners of the 2013 Young Investigator Competition, whose entries were judged on quality, clarity of science, and interest to the field of Clinical Lipidology. The NLA Young Investigator Awards were presented on Friday, May 31, after the abstracts oral... more
Yehuda Handelsman presents his talk at the 2017 Spring CLU on Lipodystrophy more
On July 24, 2015, the United States Food and Drug Administration approved the clinical use of the PCSK9 inhibitor, alirocumab, as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease who... more
Experts in the field of clinical lipidology elected as officers of medical society focused on treating cardiometabolic disorders (JACKSONVILLE, FLA.)—The National Lipid Association (NLA) recently elected new officers to serve a one-year term on its Board of Directors. The election... more
Cardiovascular disease (CVD) remains the leading cause of mortality in those > 75 years of age.1 In the United States, an estimated 84 million people have CVD, with approximately 50% of these Americans being ≥ 60 years old.2 The prevalence of CVD increases with age, from 15% in men and 9% in... more
This Fall 2023 edition of the LipidSpin on Diabesity is sponsored by NELA and SELA Chapters. The 2023 NELA Chapter and Board would like to thank all the authors, contributors, and editors who shared their expertise to make this an informative and valuable issue of LipidSpin. Despite the... more
The NLA, the sole endorser of the new Expect Consensus Decision Pathway document and partner on the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on... more
Are you excited for a new year with the NLA? While we still have so much to accomplish in 2022, there is a lot of excitement about what we will be doing as we head into 2023. The NLA has developed a series of educational activities and engagement opportunities for our members and those interested... more